S4 - Movement Disorders: Beyond Oral Levodopa in Parkinson's Disease

Event Time: Sunday April 23, 2017 1:00 pm to 3:00 pm
Topic(s): Movement Disorders
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
1:00 PM 001 Global long-term registry on efficacy and safety of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease patients (GLORIA) – final results in a subgroup of patients with dyskinesia at baseline Werner Poewe, MD
Disclosure:
Dr. Bergmann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc.. Dr. Bergmann holds stock and/or stock options in AbbVie Inc..

1:12 PM 002 ND0612, a novel liquid formulation of levodopa/carbidopa for subcutaneous infusion in patients with Parkinson’s disease achieves stable levodopa plasma levels when administered in low and high doses Nir Giladi, MD, FAAN
Disclosure:
Dr. Giladi has nothing to disclose.

1:36 PM 004 Preliminary Results of the Phase I Clinical Study Evaluating Neural Stem Cell Based Therapy for Parkinson's Disease Russell Kern, PhD
Disclosure:
Dr. Kern has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with International Stem Cell Corporation. Dr. Kern has received compensation for serving on the Board of Directors of International Stem Cell Corporation. Dr. Kern holds stock and/or stock options in International Stem Cell Corporation, which sponsored research in which Dr. Kern was involved as an investigator. Dr. Kern holds stock and/or stock options in International Stem Cell Corporation. Dr. Kern has received research support from International Stem Cell Corporation.

1:48 PM 005 Quality of Life in Homebound People with Advanced Parkinson′s Disease: Feasibility and Outcomes of an Interdisciplinary Home Visit Program Jori Fleisher, MD, MSCE
Disclosure:
Dr. Fleisher has nothing to disclose.

2:00 PM 006 Effects of a Parkinson-Specific, Interdisciplinary Approach, To Inpatient Rehabilitation Christian Benedict
Disclosure:
Dr. Benedict has nothing to disclose.

2:12 PM 007 Motor retraining (MoRe) for functional movement disorders: Outcomes from a one-week multidisciplinary rehabilitation program Alexandra Jacob
Disclosure:
Dr. Jacob has nothing to disclose.

2:24 PM 008 Outcomes of a Prospective, Multicenter International Registry of Deep Brain Stimulation for Parkinson's Disease Günther Deuschl
Disclosure:
Dr. Deuschl has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Boston Scientific. Dr. Deuschl has received personal compensation in an editorial capacity for European Academy of Neurology President. Dr. Deuschl has received royalty, license fees, or contractual rights payments from Thieme publishers. Dr. Deuschl has received research support from Medtronic: Earlystim study, Boston scientific: Vercise study (through institution).

Register Now

Related Courses